Breakthrough Math: Alexion Gains $400 Million on Asfotase Breakthrough Designation
This article was originally published in RPM Report
Executive Summary
There’s a lively debate underway as to what FDA’s new breakthrough designation means for a sponsor and for the likelihood of a product’s regulatory and commercial success. Alexion’s post-Memorial Day bump dramatizes the positive impact on Wall Street.
You may also be interested in...
What’s Breakthrough Status Worth? Analysts Ask, But Companies Don’t Have Answers
Companies receiving breakthrough designations seem just as unclear as investors about the value of the program.
PDUFA V and Investor Communications
The Prescription Drug User Fee Act reauthorization made a number of important changes to the new drug review process and programs for stakeholder engagement with FDA. It also created a number of new investor communication challenges for sponsors.
The Orphan Drug Bubble
Two former biotech high flyers are up for sale, with Amylin attracting more would-be suitors than Human Genome Sciences. The spectacle of the bidding is great. But did you know that the orphan drug company Alexion is worth more than those two companies combined?